Wall Street Zen Upgrades Biodexa Pharmaceuticals (NASDAQ:BDRX) to “Sell”

Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 15th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Down 7.1%

Shares of NASDAQ:BDRX opened at $2.63 on Friday. The business has a fifty day simple moving average of $5.24 and a 200-day simple moving average of $6.77. Biodexa Pharmaceuticals has a 52 week low of $2.55 and a 52 week high of $92.00.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.